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Abstract— Bipolar Disorder (BD), characterized by mood 
fluctuating between episodes of mood elevation and depression, 
is a leading cause of disability worldwide. Lithium continues to 
be prescribed as a first-line mood stabilizer for the management 
of BD. However, lithium has a very narrow therapeutic index 
and it is crucial to carefully monitor lithium plasma levels as 
concentrations greater than 1.2 mmol/L are potentially toxic and 
can be fatal. The current techniques of lithium monitoring are 
cumbersome and require frequent blood tests with the 
consequent discomfort which results in patients evading 
treatment. Dermal interstitial fluid (ISF), an underutilized 
information-rich biofluid, can be a proxy for direct blood 
sampling and allow lithium drug monitoring as its lithium 
concentration is proportional to the concentrations in blood. 
Therefore, in this study we seek to investigate the measurement 
of lithium therapeutic concentrations in artificial ISF. Our study 
employs a colorimetric method, based on the reaction between 
chromogenic agent Quinizarin and Li+ ion which can be detected 
using optical spectroscopy in the visible region (400-800 nm), to 
determine lithium levels in artificial ISF. The resulting spectra 
of our experiments show spectral variations which are related to 
lithium concentrations in spiked samples of artificial ISF, with a 
correlation coefficient (R) of 0.9. Future work will focus on 
investigating the feasibility of utilizing ISF for real-time and 
minimally-invasive lithium drug monitoring. 
 
I. INTRODUCTION 
Bipolar disorder (BD) is a recurrent psychiatric illness 
characterized by mood fluctuating between episodes of mania 
and depression. BD is a leading cause of disability worldwide, 
with an unknown biological basis and unsatisfactory 
treatment. Lithium remains the “gold standard” for both acute 
and maintenance treatment of bipolar disorder, reducing the 
risk of relapse and suicide [1]. However, lithium has a narrow 
therapeutic range and lithium plasma levels greater than 1.2 
mmol/L are potentially toxic and can be fatal when the levels 
exceed 2.0 mmol/L, hence blood levels must be frequently 
monitored [2][3]. Monitoring of blood levels is performed on 
a weekly basis upon commencement of lithium therapy, and 
monthly once the required therapeutic dose is established [3]. 
The current techniques of blood lithium measurement, namely 
flame emission photometry (FEP) and atomic absorption 
spectroscopy (AAS), are complex and expensive laboratory 
methods that cannot be translated into point of care devices for 
personal monitoring. Previous studies have reported 
employing electrochemical methodologies such as ion-
selective electrode (ISE) and electrophoresis for lithium 
monitoring, which also have limitations related to interference 
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with other ions and need for sample filtration as well as 
constraints associated with cost and simplicity of the 
instrumentation [4][5]. Furthermore, the need for regular 
monitoring via venepuncture is one of the main reasons that 
can lead to lithium toxicity or treatment nonadherence [2]. 
Therefore, development of a minimally-invasive monitoring 
method will be a major advance in the management of BD.  
Efforts have been made in order to develop point-of-care 
lithium monitoring devices utilizing matrices such as saliva 
and sweat which have shown limitations related to drug 
instability and the potential presence of contaminants [6][7].  
Dermal interstitial fluid (ISF), the fluid bathing the viable 
tissue of skin, is an accessible and reproducible matrix that is 
suitable for minimally invasive detection of biomarkers and 
drugs with good correlation with venous blood [8]. 
Concentration of lithium in the ISF is suggested to be 
correlated with venous blood [9], hence we seek to explore the 
detection of lithium in this matrix. Previous studies have 
combined potentiometric sensors with reverse iontophoresis 
(RI), used for extraction of lithium across the skin, in order to 
achieve monitoring of lithium in ISF [10][11]. However, these 
methodologies have several issues including the need for quite 
complicated technology, prolonged preparation time, and lack 
of sensitivity [12]. Our group has demonstrated that optical 
spectroscopy techniques provide accurate detection of lithium 
concentrations in blood. Our aim is to further investigate this 
methodology in interstitial fluid as it provides a more 
accessible source for monitoring lithium and developing a 
minimally-invasive sensor. Minimally invasive, continuous 
monitoring of lithium in the interstitial fluid offers a promising 
route of personalisation of medication regimens and will allow 
bipolar patients to monitor the medication which will greatly 
reduce the risk of adverse effects during the course of their 
treatment [13]. 
 
II. MATERIALS AND METHODS 
A. Chemicals and reagents  
4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid 
(HEPES), calcium chloride (CaCl2), potassium chloride 
(KCl), magnesium sulfate (MgSO4), sodium chloride (NaCl), 
sodium phosphate monobasic (NaH2PO4), and saccharose 
were obtained from Sigma Aldrich (St. Louis, MO, USA). 1,4-
Dihydroxyanthraquinone 96% (Quinizarin), Methyl sulfoxide 
99.9% ((CH3)2SO), Sodium hydroxide (NaOH), Sodium 
carbonate (Na2CO3), and Lithium carbonate 99.9% (Li2CO3) 
were obtained from Fisher scientific (Waltham, MA, USA). 
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All solutions were prepared using deionized water (The 
Deionised Water Company, Suffolk, UK).  
B. Preparation of artificial interstitial fluid  
To prepare the artificial interstitial fluid (ISF), 2.5 mM 
CaCl2, 10mM Hepes, 3.5 mM KCl, 0.7 mM MgSO4, 123 mM 
NaCl, 1.5 mM NaH2PO4, 7.4 mM saccharose were mixed, 
and the solution was adjusted to pH 7.5 using Thermo 
Scientific STAR A211 pH meter [8].  
C. Sample preparation  
A stock solution of 60 mM Lithium was prepared by 
dissolving 1.1082 g Li2CO3 in 250 ml dH2O. The Li2CO3 
solution was then further diluted to make a set of solutions with 
the following concentrations: 6, 12, 18, 24, 30, 36, 42, 48, 54 
mM. Thereafter, samples of artificial ISF prepared earlier were 
spiked with lithium by mixing 1 mL from each concentration 
of Li2CO3 (i.e. 6, 12, 18, 24, 30, 36, 42, 48, 54, and 60 mM) 
with 29 mL of artificial ISF. Therefore, 10 samples of 30 mL 
spiked ISF with lithium concentrations ranging between 0.2-2 
mM were achieved. 
D. Reagent preparation  
The following reagents were prepared for colorimetric 
analysis of lithium using Quinizarin: 0.1 M of NaOH, 0.25 M 
of Na2CO3, 99.9 % (CH3)2SO and 1 mM of Quinizarin in 
(CH3)2SO. A 1 M stock solution of Sodium hydroxide was 
prepared by dissolving 10 g of NaOH in 250 mL dH2O. A 0.25 
M stock solution of sodium carbonate was prepared by 
dissolving 5.299 g of Na2CO3 in 200 mL dH2O. 1 mM of 
Quinizarin solution was also prepared by dissolving 60 mg of 
1,4-dihydroxyanthaquinon in 250 ml of dimethylsulfoxide 
(CH3)2SO.  
E. Optical measurements of lithium in artificial ISF  
An amount of 50 μl from ISF samples spiked with different 
concentrations of lithium were pipetted into a test tube. A 
sample of ISF without lithium was also included as the control. 
Prepared samples of ISF were then mixed with 100 μL of 0.1 
M NaOH, 10 μL of 0.25 M Na2CO3, 40 μL of water, 2.15 mL 
of 90 % (CH3)2SO and 50 μL of 1mM of Quinizarin in 
(CH3)2SO. All samples were kept in a thermostatic bath 
(Grant InstrumentsTM TC120 Series Heated Circulating Bath) 
at 25o for 30 mins prior to testing.  
Data was acquired using a dual beam spectrophotometer 
(Model: Lambda 1050, PerkinElmer Corp, Waltham, MA) 
using plastic cuvettes. The instrument was setup to acquire 
three spectra from samples in the spectral region between 400-
800 nm and at increments of 1 nm. The detector system was 
set to use the PMT detector for up to 860.80 nm, where the slit 
size was kept fixed at 2 nm, and for up to 900 nm InGaAs 
detector was used where the slit size was kept on “servo 
mode”. The gain settings for PMT and InGaAs detectors were 
set on “Auto” and 1, respectively; while the response time for 
both detectors was set on 0.2 seconds. The reference and 
sample attenuators were both set to 100%. UV Winlab Data 
Processor and Viewer program was used to display the spectra, 
carry out arithmetic and derivative processes, and export data 
as excel files to generate line graphs and perform regression 
analysis using IBM SPSS Statistics.  
III. RESULTS  
A. Lithium can be detected in the visible region based on 
its reaction with the chromogenic agent Quinizarin  
Lithium, like other alkali metals, shows relatively poor 
chemical coordination, hence it does not have any optical 
signature in the spectral region. However, its high charge 
density provides great affinity to ligands with donor oxygen, 
and several chromogenic organic reagents such as 1,4-
dihydroxyanthraquinone (Quinizarin) have been used as 
complexing agents of Li+. In dimethyl sulfoxide medium 
(90%) and in the presence of sodium hydroxide and sodium 
carbonate, the reaction of Li+ ion with Quinizarin results in 
the development of a bluish-violet color which can be 
detected using visible spectrophotometry [14]. Therefore, we 
sought to investigate the colorimetric determinations of 
lithium levels in artificial ISF based on the mentioned 
methodology. In order to achieve this, artificial ISF was 
prepared and spiked with therapeutic concentrations of 
lithium from 0.2 to 2 mmol/L. Raw spectral data of lithium 
spiked ISF samples in the presence of Quinizarin are shown 
in (Fig. 1A). The original spectra in (Fig. 1A) represents two 
absorption bands around 560-580 nm and 600-630 nm, which 
represents the complementary color to the wavelengths 
absorbed. In order to manifest the peaks of ISF samples 
spiked with 0.2-2 mM of lithium, the spectrum representing 
the sample containing no lithium was subtracted from the 




Figure 1. Raw spectra (A), and difference spectra (B) of therapeutic 
concentrations of lithium (0.2-2 mM/L) in artificial interstitial fluid, tested 
using colorimetric method based on the reaction of lithium ion with 
Quinizarin.  
  
B. The variations in absorption peaks are proportional to 
the concentrations of lithium  
 
From the difference spectra illustrated in (Fig. 1B), it can be 
determined that there are variations in absorption which seem 
to be proportional to the concentrations of lithium, with the 
absorption values increasing as the concentration of lithium 
in the spiked samples of artificial ISF increases. In order to 
further investigate these variations, a second-order derivative 
is applied to separate the peaks of overlapping bands and 
remove the spectral interferences and baseline effects which 
helps increase the selectivity of the assay. Second derivative 
spectra of the therapeutic concentrations of lithium is 
demonstrated in (Fig. 2). Second derivative gives negative 
peaks for each crest and trough in the spectrum. As depicted 
in (Fig. 2) there are variations in absorption minima between 
620-640 nm regions, which correlate with the amounts of 
lithium in the sample. Less significant changes are also 
observed in minima absorptions between 560-580 nm. 
Therefore, wavelengths from these prominent regions can be 





Figure 2. Second derivative spectra of therapeutic concentrations of lithium 
in artificial interstitial fluid in the range 400-800 nm. Prominent bands found 









C. Levels of lithium in ISF can be determined using few 
selected wavelengths only  
From the difference spectra illustrated in (Fig. 1B), it can be 
determined that there are variations in absorption peaks 
between 540-570 nm and 590-615 nm which seem to be 
proportional to the concentrations of lithium. In order to 
investigate this correlation, linear regression analysis was 
performed using two wavelengths from the prominent peaks 
(Fig. 3A and B). Higher correlation of determination (R2) was 
achieved for the second peak compared to the smaller peak. 
In accordance with Beer-Lambert law, with the increase in 
concentrations of lithium from 0.2 to 2 mM there is an 
increase in the absorption values in the identified regions. 
From the Coefficient of Determination of 90% achieved from 
the regression analyses it can be concluded that the identified 
regions can be used for lithium concentration prediction in 
ISF with high accuracy.  
 
Figure 3. Linear regression analysis of absorption variations of different 
lithium concentrations in the region between 540-570 nm and 590-615 nm of 
the difference spectra. (A) Absorption variations at 560 nm representing the 
first peak. (B) Absorption variations at 604 nm representing the second peak. 






IV. DISCUSSION AND CONCLUSIONS  
Side effects and toxicity burden associated with lithium 
medication along with the crucial need for regular monitoring 
are the main reasons for lithium discontinuation and treatment 
nonadherence. Using the blood as the matrix for analytical 
detection of an analyte has the obvious drawback of having to 
do repeated blood tests. Consequently, facile monitoring of 
analytes of interest in a more accessible biofluid will be the 
main focus of next generation of devices for personal 
healthcare monitoring. 
The accessible location of dermal ISF and the correlations 
found between blood and ISF levels of lithium resulted in our 
research effort for determining lithium therapeutic 
concentrations in ISF. This study was set out with the aim of 
detecting various concentrations of lithium in artificial ISF 
using a colorimetric method based on the reaction between Li+ 
ion and Quinizarin. The resulting spectra of the experiments 
showed spectral variations which could be related to lithium 
concentration in spiked samples of ISF. Furthermore, linear 
regression analysis was conducted which showed a high 
correlation coefficient, meaning that the absorbance values at 
the wavelengths of interest were linear and correlated to the 
lithium concentrations. Therefore, the undertaken studies have 
demonstrated the feasibility of the proposed colorimetric 
method for determinations of lithium levels in artificial ISF 
using few selected wavelengths only.  
So far, our results demonstrate the clear relationship 
between acquired spectra and lithium levels in artificial ISF 
samples. In our future studies we will also perform reference 
flame photometry measurements on ISF samples containing 
unknown levels of lithium to further evaluate our measurement 
technique. Moreover, biological ISF samples will be used to 
validate the results reported in this study using artificial ISF 
against a reference. In addition to quantitative determinations 
of blood lithium levels, the degree of specificity to lithium 
using the proposed method should also be investigated by 
including sodium in the samples as it is usually present at high 
concentrations in biological fluids.  
Ultimately, we will investigate whether this method can be 
employed into a minimally invasive sensor for extraction and 
on device measurement of lithium in dermal ISF. 
Spectrophotometric measurement of therapeutic levels of 
lithium in interstitial fluid can provide the monitoring of this 
medication with an enhanced degree of specificity. The 
reported results give us a precise understanding of the light-
lithium ion interaction in the optical spectrum region and its 
potential for development of a minimally-invasive lithium 
sensor. Therefore, the proposed methodology can be employed 
into a microneedle-based sensor to achieve facile extraction of 
ISF and rapid determination of lithium concentrations. In 
conclusion, determinations of lithium in ISF, an information-
rich and accessible fluid, can support future development of a 
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